**Correction to**: *British Journal of Cancer* (2016) **115**, 188--194. doi: [10.1038/bjc.2016.185](/doifinder/10.1038/bjc.2016.185); Published online 28 June 2016.

Upon publication of the above paper in the *British Journal of Cancer*, the authors identified several errors in their manuscript and [Supplementary Material](#sup1){ref-type="supplementary-material"}.

[Table 3](#tbl3){ref-type="table"} contained minor rounding errors and was incorrectly formatted. The correct table has been reproduced below.

On page 5, the second sentence in the discussion section omitted a reference and contained a minor numerical error. The sentence should read:

'Indeed, the median OS of patients in the *nab*-P+Gem group who received a 2L treatment was over 4 months longer than the median OS with *nab*-P+Gem in the ITT population (12.8 *vs* 8.7 months; [@bib2]; [@bib1]) and over 6 months longer than the median OS with *nab*-P+Gem in patients who did not receive 2L therapy (12.8 *vs* 6.3 months).\'

[Supplementary Figure 1](#sup1){ref-type="supplementary-material"} has been replaced in the original supplementary file list, with a number of values having been changed.

The authors apologise for these oversights.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### Multivariate analyses of total OS, post-first-line OS, and survival time from the start of second-line therapy to death (OS2)

  **Covariate**[a](#t3-fn2){ref-type="fn"}                                                     **HR (95% CI)**    ***P*****-value**
  ------------------------------------------------------------------------------------------ ------------------- -------------------
  **Total OS (includes treated patients with or without a 2L therapy;** ***n*****=741)**                         
  Treatment group (*nab*-P+Gem *vs* Gem alone)                                                0.63 (0.54--0.74)        \<0.001
  2L therapy (with *vs* without)                                                              0.50 (0.43--0.59)        \<0.001
  NLR at baseline (⩽5 *vs* \>5)                                                               0.59 (0.50--0.69)        \<0.001
  KPS at baseline (70--80 *vs* 90--100)                                                       1.33 (1.13--1.55)        \<0.001
  Presence of liver metastasis (yes *vs* no)                                                  1.50 (1.22--1.85)        \<0.001
  CA19-9 level at baseline (continuous)                                                       1.16 (1.05--1.29)         0.005
  Age at baseline (\<65 *vs* ⩾65 years)                                                       0.88 (0.75--1.02)         0.089
  **Post-1L OS (includes treated patients with or without a 2L therapy;** ***n*****=793)**                       
  Treatment group (*nab*-P+Gem *vs* Gem alone)                                                0.73 (0.63--0.85)        \<0.001
  2L therapy (with *vs* without)                                                              0.47 (0.40--0.54)        \<0.001
  NLR at end of 1L (⩽5 *vs* \>5)                                                              0.60 (0.52--0.70)        \<0.001
  KPS at end of 1L                                                                                                         
   90--100 *vs* ⩽60                                                                           0.46 (0.37--0.57)        \<0.001
   70--80 *vs* ⩽60                                                                            0.57 (0.47--0.70)        \<0.001
  PFS, months (⩾4.4 *vs* \<4.4)[b](#t3-fn3){ref-type="fn"}                                    0.78 (0.67--0.91)         0.002
  Geographic region (North America *vs* others)                                               0.86 (0.74--1.00)         0.051
  **OS2 (only patients who received 2L therapy;** ***n*****=346)**                                               
  Number of metastatic sites                                                                  1.15 (1.02--1.29)         0.018
  NLR at end of 1L (⩽5 *vs* \>5)                                                              0.76 (0.60--0.97)         0.027
  KPS at end of 1L                                                                                                         
   90--100 *vs* ⩽60                                                                           0.53 (0.35--0.81)         0.003
   70--80 *vs* ⩽60                                                                            0.66 (0.44--1.00)         0.052

Abbreviations: CA19-9=carbohydrate antigen 19-9; Gem=gemcitabine; HR=hazard ratio; KPS=Karnofsky performance status; *nab*-P=*nab*-paclitaxel; NLR=neutrophil-to-lymphocyte ratio; PFS=progression-free survival; CI=confidence interval; OS=overall survival; 2L=second-line; 1L=first-line.

Covariates tested for each multivariate analysis are listed in the Materials and Methods section.

In this study, the median PFS for the entire intention-to-treat population was 4.4 months.
